Welcome to the official podcast of The GOG Foundation, Inc.—a nonprofit organization dedicated to advancing excellence in clinical and scientific research for gynecologic cancers. From ovarian and uterine to cervical, vaginal, and vulvar malignancies, our investigators and institutions are at the forefront of innovation, shaping the future of cancer care.
Each episode features leading experts, groundbreaking trial insights, and real-world stories that illuminate the evolving landscape of gynecologic oncology. Whether you're a clinician, researcher, patient advocate, or survivor, join us as we explore the science, the people, and the progress driving better outcomes and quality of life for patients everywhere.
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (https://clinicaltrials.gov/ct2/show/NCT07044336)
This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following platinum based chemotherapy and anti-PD-1/anti-PD-L1 therapy.
★ Support this podcast ★ (https://www.gog.org/new-horizons/)
25 Sept 2026
GOG-3133 FRAmework-01 Clinical Trial Update
We are pleased to share that the video recording for the GOG-3133 FRAmework-01 clinical trial is now available for on‑demand viewing.
In this video, Dr. Roisin O'Cearbhaill and Dr. Bhavana Pothuri provide a high-level overview of the study, including the scientific rationale, trial design, and key features of the three cohorts evaluating patients with platinum-resistant and platinum-sensitive ovarian cancer.
We encourage all investigators and research staff involved with GOG-3133 to review the video and share it with members of their study teams. The video is intended to support understanding of the study and prepare sites for successful patient identification and enrollment.
Thank you for your continued dedication to advancing ovarian cancer research. If you have any questions about the study, please reach out to the GOG-3133 study team.
Contact Study PIs:
Roisin O'Cearbhaill, MD
Memorial Sloan Kettering Cancer Center
ocearbhr@mskcc.org (mailto:ocearbhr@mskcc.org)
Bhavana Pothuri, MD
NYU Langone
bhavana.pothuri@nyulangone.org (mailto:bhavana.pothuri@nyulangone.org)
★ Support this podcast ★ (https://www.gog.org/new-horizons/)
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
